A CFO's Prescription For Biopharma Success With Allan Shaw Business Of Biotech · 21 Mar 2021 Source: https://www.buzzsprout.com/1011661/episodes/8158734-a-cfo-s-prescription-for-biopharma-success-with-allan-shaw.mp3 Transcript: https://podcasts.opennash.com/shows/business-of-biotech/a-cfos-prescription-for-biopharma-success-with-allan-shaw-01943e/ (via OpenNash Podcasts, machine-generated) Welcome back to the business of biotech. I'm your host, Matt Pillar. And today we're once again joined by friend of the show, Allan Shaw. Alan, it's always great to have you back. Thanks, Matt. Great to be back. Yeah. So we're going to spend today's show painting an illustration of success in biopharma. But before we get started, I wanted to take a minute to acknowledge that when this episode airs, we will be celebrating our one-year anniversary of the Business of Biotech podcast, which coincides with the one-year anniversary of our partner and its production, Cytiva. Needless to say, Alan, it has been a wild year to launch a podcast focused on the business of biotech, But I want to ask you to help us commemorate the milestone. And in the spirit of nostalgia, I'm going to throw a curveball question at you. So if Allan Shaw is thinking about the past 360 plus days in this space, wild as they've been, And share with us a key moment or highlight from your work in this space that's kind of drawn out of this crazy time. Just sort of, as I said, to commemorate in a nostalgic way the fact that we're a year into this project. Certainly, that's a really very interesting question given the backdrop of the last year. There's a lot of different ways one can really go on that. I think in terms of the industry, notwithstanding a year that most people would prefer to not remember, I would say from an industry, it's been a remarkable year on really a seminal year on many levels. But I think to not dominate this conversation with that, that could probably be an episode in itself. I think maybe we did one. But anyway, I would speak to the fact of the industry broadly, you know, going into this year, I would say that the biopharmaceutical industry was the favorite whipping boy of the media and of the world. and you know and it was always ironic to me that when you consider the level of disdain that that the industry was subject to which is usually you know reserved for industries causing global health in this problem such as tobacco and I always found it ironic that you know we arguably provided more more positive impact on humanity uh relative to so many other ways the resources are allocated like defense or other things like that. So, you know, to me, what I thought was really nice for a change is I think there's been a paradigm shift in terms of how the industry is now viewing the biofarmer sector. And I think the way the industry is pulled together is one. And I mean, it's just unbelievable when you reflect that in less than a year, we've been able to go from discovery to actually having drugs available to vaccinate against COVID-19. And I think the world is appreciating that. And I think you see the capital allocation that's moving into the industry on the capital markets speaking on that. So I don't see any of this as accidental, right? I think it's really recognition that our industry is arguably best to quit to make a positive impact on society. And that's refreshing. It's really nice that that's finally aligned itself better. Yeah, I joined at, I guess, a fortuitous time. I joined the space because I wasn't here for the, you know, the whipping that the industry took for so long. It's been all sunshine and roses since I've joined the space. And, you know, I think that It's a great point that you make about this time that we're in. And I think it frames up today's conversation quite nicely. You know, we're going to talk about the elements, the sort of the building blocks, elements of success in the space. And I think that it's a timely discussion because those elements may look different two years from now. They may look different 12 months from now, depending on where we're at. So before we get into these key design elements in the painting of a successful biopharma, I wanted to get your perspective on where we're going with this conversation. We'll talk some specifics in terms of those design elements, but what's the outcome we're looking for? How do you define success in biopharma? you know success means different things to different people you know i think from my from my perspective you know success in biofarmers being able to bring a novel impactful drug to help solve a medical problem to help patients uh to help change the standard of care or even create a standard of care where they're not alternative therapies. You know, there's a lot of therapies that, you know, just by definition, if there's not a therapeutic alternative, they're generally misdiagnosed. So, you know, so to me, that is success to really be able to make an impact on patients. And that's like what I like about BioFarmer, you know, you're doing good by doing good. But that's a long journey when you look at the various steps along the way. And then when you take a step back, that's like climbing a mountain. It's a huge mountain. Some people say bringing a drug to the market is like getting to heaven. So when you take a step back, I think you need to look at the incremental steps to get you there. And there's a lot of incremental steps that if you don't get those parts right, you're never getting to the top of the mountain. But in terms of endpoints, we look at clinical endpoints. I would say endpoint is bringing an impactful drug to the market. Sure. Yeah. When you talk about those incremental steps, I've spent a lot of time on this podcast and in this position talking with biopharma execs, leaders of biopharmas, large, small, and in between. And one thing that I've learned is that there's not always a super clear chronology in those incremental steps, right? The continuum is not always prescriptive, let's say. So, I'm not sure, you know, I guess I'd ask you, if we start looking at those increments, you know, those building blocks and the successes that each of them represent, do you try to ascribe in the work that you do with biopharmers, do you try to ascribe some sort of a chronology, a methodology in the approach, you know, step one, step two, step three, or not so much? You know, that's an interesting question. You know, I've never thought about it as formally as you put forward like that. You know, a lot of it has become, I guess, instinctive or becomes really more embedded in terms of your philosophy or your values in terms of how you approach things. You know, kind of like your kids, you know, you want to establish the right value system because you can't always be with them at the end of the day, but you want them to be able to make those innate decisions and know what to do when those situations come. And similarly, so I don't go in with a new situation, say these are Alan's rules or these are the ways you need to go about doing it because every situation has its own life and there's a reason for why they're doing things. But I think there is a common theme in terms of mistakes that people make or short-sightedness or, I guess, another way where I see where I, you know, low-hanging fruit where it's very easy to make a positive impact at the end of the day when you get in there. So, you know, speaking to some of those thoughts, you know, I think it all begins and ends with efficient and optimal resource allocation. You know, and I think that's something that when there's a lot of liquidity and a lot of money being thrown around, it's somewhat overlooked. And I think, and bad decisions and bad allocations get masked as well. And we could spend a lot of time talking about that. But, you know, I think it really capital resource allocation, how you prioritize things and your focus. I think it begins and starts from there and then you can expand out. Yeah. When you say masked, you're saying like, you know, capital is relatively easy to get your hands on right now. So it's easy to kind of cover up the mistakes or pay for, if you will, the mistakes? Yeah, absolutely. No question about it. Yeah. Well, you and I have had conversations about the fact that this time that we're in, this extraordinary time that we're in, isn't necessarily going to, it's not going to be sunshine and roses forever. So when it comes to capital and capital efficiency, what advice do you give around, hey, I realize that you're flush perhaps right now. But as I said, you may not be in 12 months, you may not be in two years. What advice do you give around allocation of that capital, even in these flush times that we're in right now? I think it's natural. I think we've all seen the movie that when there's more capital available, there's generally less discipline with the process of allocating in terms of the projects that you do and even the level of risk that you take on as an organization. So, you know, I usually urge people to generally try to apply the same level of discipline, whether they have $1 million in the bank or $100 million in the bank or whatever that that number is, you know, and I think it's really important to remain strategic as you as you do this and focus on what you what needs to be done to create value as opposed to necessarily pander to the market hubris. to what the market, what you think the market wants you to be doing. Yeah, yeah. There's a fine, you know, that's a tough thing, I think, probably, especially for folks who are new in the space to define because there's a, you know, there's obviously competition on the product front, right? Competition to that end point that you talked about, but there's also competition to perception. You know, you talk about competitive advantage and you talk about how to relate that to capital efficiency and capital conservatism, if you will. It's sort of a philosophical question, but how do you determine money well spent when, you know, perhaps in this time in particular, your peers, your competitors are spending a lot of money on probably perception that, you know, maybe isn't such a good idea. Yet there's got to be pressure to follow suit, right? So where's the balance? Yeah, you know, it's what you say is easier said than done, right? Or what I'm saying is easier said than done, I guess, is better put. In response, you know, I think you still need to kind of not fall in the trap of keeping up with the Joneses, right? Because that, that, some of that's premised on the fact that the spigot is going to continue to be available. And, you know, those that are doing that, when the music stops, they're going to get caught out at the end of the day. So, you know, I, so therefore, well, it's easy to fall into that trap. You know, and I see it, I see trends there, you know, You saw that a couple of years back. Every oncology company wanted to suddenly be in IO. Now I think it's fashionable to be in precision oncology. You're seeing people kind of putting themselves into the boxes because those are the flavors of the day. But I think at the end of the day, none of that is durable and none of that's sustainable. It's all about execution. So, you know, I would ultimately respond that you need to focus on executing and creating data and fundamentally de-risking, you know, the assets that you've chosen to develop. And, you know, and if there's read through and there's risks, I would just urge you to develop the risk, whatever has that read through before you start putting two programs at risk and putting investors money at risk. And what I'll also urge people always when they're advocating or being a little cavalier is to make it a little personal. So if this was your money, would you be advocating doing this? You'll get different answers more times than not when it's their money that's being at risk as opposed to someone else's. Sure. Yeah. Yeah. When it comes to execution, I know that the talent is a big part of execution. So let's talk about that. And, you know, we can tie back to that kind of incremental pictures of success. What does success on the journey look like as it relates to talent acquisition and retention for that matter? You know, it's to me, it all begins and ends with talent. You know, it goes back to jockeys and having the right folks. folks. And, you know, and I have a couple of, not surprisingly, a few thoughts on this. Excuse me. So, you know, first, first and foremost, you know, given the choice of how, and I may have said this before too, but I think it's an important point and it sets the stage, you know, given the choice of having a superior asset and a middling management team, or a superior management team and a middling asset, I would always pick the latter. You know, the jockeys can always create value, but a great asset can be destroyed if you don't have the right people developing it. And so I think that really underscores and speaks to the need for jockeys and trying to have the best folks available to move the needle. People who've had experience, you know, in this space, time is the enemy and the shortest distance between two points is a shortcut. So, you know, if you've got people who have experience and know how to get things done and can learn from their past, I think there is a strategic advantage there. And I think in this marketplace right now with COVID, you know, there is a lot of negative, but one of the silver linings now is that we've debunked the fact that someone has to live in your zip code to work. So I think you now have the ability to really, You have global access to the best talent available. You're no longer stuck to the hubs of Cambridge or the hubs of San Diego or Carolina or Philadelphia, for that matter. And you don't need to relocate. I mean, to me, the idea of having to relocate for the job is, you know, when you talk to kids about that, they'll be laughing at you just like they'll laugh at you. What do you mean you didn't have a mobile phone? What do you mean you didn't have a computer when you were in college? You know, I feel like the way my grandfather spoke to me. Yeah. But at the end of the day, you know, that's powerful. And then lastly, you know, on this, and then we can, you know, go anywhere else. But I would say as an industry, it's really ironic. and that is the fact that we we go all over the world trying to get the best science in the world but when it when it but when it comes to trying to find talent in our industry we're we're somewhat uh we artificially limit ourselves just going with resources that are from the industry itself. And I think given a lot of the paradigm shifts and the change of how we need to evolve as an industry, I think being able to bring people in from other industries and cross-fertilize that and get out of some of this insular thinking that I think predominates our sector more than probably any other is fundamentally critical. And I've often, I ironically have looked at this is, you know, we fish the entire global ocean for technology and for innovative assets. But when we look for talent, we actually go into a small little pond. And to me, there's room for improvement on that front. Yeah. And so I've got a two-part follow-up question on that for you. Again, in the context of the current market that we're in, is it X more difficult to recruit and retain talent in a market that's flush with cash? And arguably, I don't even think it's arguable, short on talent, right? One, is that difficult? And how do you overcome that? And how do you overcome that kind of leads to part two of the question. I fancy you sort of, you know, in your financial role as leaning fiscally conservative. Do you bend a little bit on the talent front? Like, do you advocate a little bit more for, hey, it's hard to come by. It's central to success. So, yeah, spend a little bit more. Spend a little bit more on your people, your jockeys. No, it's a fair question. You know, in this marketplace, retention of people are really difficult. You know, you know, certainly in the Boston, Cambridge, you know, there's a lot of anecdotal stories about people just the turnover, just being incredible people just crossing the street, you know, and there's certainly nothing that's changed. So I think in terms of retention, that's going to become strategic in terms of how you retain people. And I think a lot of that has to come to the programs. And I think we're probably going to need to be more generous with the equity. Right. I think, you know, I think the, you know, cash is cash and you can pay people. But, you know, you know, the way I try to explain it to my family is that, you know, the cash, you know, covers your overhead. You know, if you want to create wealth and ultimately move the needle, it's good. Wealth creation is associated with the equity. So I think the equity is going to be something that people may need to, there may be new metrics there. And notwithstanding my financial discipline, you know, to me, I view this as very much as a team sport and that you need the right actors and you need the right horses. And so I try to be pragmatic at the end of the day. And, you know, if that's the cost of doing business, then, you know, I have no issue with that. You know, it's a matter of your priorities. But to me, it's all about getting back to success and how do you execute. And to me, to improve the probability of success in terms of execution, it comes again down to the people at the end of the day. Yeah. The business of biotech is brought to you in partnership with Cytiva. Together, we're committed to helping the leaders of new and emerging biopharma companies navigate the financial, organizational, human resources, and regulatory waters you'll encounter on your way from discovery to the clinic and beyond. Check out a host of useful resources for biotech leaders at Cytiva's Emerging Biotech Accelerator at citivalifesciences.com backslash emergingbiotech. That's C-Y -T-I -V-A lifesciences.com backslash emergingbiotech. Let's talk about time. You know, traditionally, the pursuit of that endpoint, taking a biologic therapy to market, has been, and it remains a long game, right? I mean, to your point, it's a marathon. It's a long journey. But at the same time, there's, I think, in today's market, perhaps fed by the speed at which we've moved through COVID therapeutics and the COVID vaccine, there's a heightened sense of urgency, I think, generally around development timelines and time to market. One, I'd ask, do you agree that there is sort of a heightened sense of urgency? And two, what does that mean from a biopharma leader's perspective in terms of how quickly do we need to move? you know um you know i think it's an excellent question that you pose you know time is the is the enemy so uh you know to me you gotta you can't waste time you you know there's a competitive landscape there's come out capital market risks and and everything is very fluid and you know and it's also to me, time is money. You know, if you look at the time, people don't consider this, when you have delays in your development activity, you know, not only, you know, some people think they're saving money, right? Oh, I got more money in the bank. But in fact, you're still burning overhead. So it's actually, you've actually incrementally increased the cost of success at the end of the day. So, you know, to me, there's no value with overhead, you want to minimize it, but be responsible at the end of the day. So that's one aspect of it. And I think a lot of it is, you know, you want, and because there's not only the time of overhead, but there's the time of running bad experiments, right? And the cost of running bad experiments. So, you know, I'm for one is kill early. You know, you want to run the killer experiments as soon as you can to answer the important questions. And once you answer those questions, run the next set of killer experiments to answer the next set of questions. You know, so, you know, if you're answering, if you're asking the right questions up front and running the right tests, you know, you can get, you can ultimately save yourself time and money by pushing drugs aside that aren't, that don't hunt. And at the other hand, you know, you validated your mechanisms. And that's not only going to allow you to move more expeditiously, but you'll also be able to raise the right capital and avoid the trap of this being a job. I think a lot of people view this as, you know, this is their job. So they want to protect their job. And it's not the focus is drug development. And let's figure out what doesn't work, right? You know, so much, even when you get into the clinic, it's of low probability of success? Let's answer these questions quickly. And too many times the wrong experiments are not run as quickly as they should be. Yeah, it's a really interesting point. I recently had a conversation on this podcast with Dietrich Stefan, who's the CEO at New Base Therapeutics. And we talked about this very issue, you know, the fail fast, fail cheap kind of paradigm. And And I'm interested in your take on this because there's a pressure, I think, among biopharmas around public failure, which I think internally, you know, I've had conversations with several CEOs in this space about this. Internally, they've realized we celebrate failure. To your point, killer experiments are a good thing. You know, if we're ready to push something to the curb and focus our efforts on something that's got more problems, that's a good thing. But yet there's this exterior pressure, right, that says failure is bad. You know, if you're killing experiments, if you're conducting killer experiments and moving things aside, it's, you know, the perception is failure. And that's a bad thing from the market's perspective. It's a bad thing from a PR and IR perspective. How do we change that paradigm? Is it worth fighting? Is it worth fighting? And how do you strategically, you as an advisor, how do you strategically approach that? It's a tough question. It is a tough question, but it's a fair question and it's on point. You know, people don't like failure, right? That's certainly something people avoid. The public doesn't like failure, particularly if you're looking at this as your job and you're looking to raise more money. But, you know, you can't be an ostrich either. We know that that hasn't worked very well for them. And there's a day of reckoning, I think, too, right? You either have the data and really have the data and put it up or shut up and go home. I do think there's a lot of folks that do kind of try to focus on a hypothesis. And I think you want to test that hypothesis and it works or it doesn't. I think a lot of times people try to put that square peg in a round hole. And that's where you get into. I think you get into issues of keep pushing the same premise. You know, not to beat up on Alzheimer's or the amyloid plaque hypothesis, but that's a classic example of people really sticking very doggedly at a hypothesis in the face of scientific evidence that seems to suggest something else. So, you know, you know, so I think, you know, one of the attributes, I think, that are associated with the dynamic that you speak to is the fact that if people kill that program, do they have anything else? And that that gets into, you know, I think Maslow's hierarchy of needs and survival, you know, so it's not an objective assessment anymore. So, you know, I would also say that it's important to try to not be so single threaded in an industry where there's a high level of clinical and development attrition, given that mostly everything you touch is going to fail. You know, to have a single threaded development program is sowing the recipes of going out of business. You know, I think you want to develop a platform or a pipeline that gives you a couple of different ways to win and have multiple shots on goal. You know, an example that I would point to is one of my former companies, Syndax, which I helped take public a couple of years ago. And we did that with an HDAC, a Tinnostat, which was in phase three and had a lot of promise and IO, but it was one molecule. Yeah, we had a lot of different programs. And again, there were different ways to win there. But we knew one of the advantages of going public was that it would help enable us to build out a pipeline of different assets with different mechanisms. So if something didn't work, you know, we weren't done. And, you know, suffice to say the Tennis Stat program is no longer in development for a number of different reasons. But to the team's credit, you know, we within six months, we brought in an antibody that's showing some promise. The company continued to bring in assets. They have an incredibly exciting menin inhibitor now. And that's really the fundamental basis of the company's investment thesis. And it holds incredible promise. But that's because they weren't wed to the one idea. They were scientifically objective. They ran the experiments until the answers proved something else. But at the same point, they weren't wed to that. And they built up in parallel. They built up additional pipeline assets and different shots on goal. And they've now positioned themselves for success. Yeah. Yeah. I want to talk about, I want to lump a couple of things together here. Discipline. And you've talked about, you know, running your business without focusing on the industry hubris. Reminds me of I ran. I was a runner in high school and college and I had a track coach in college. I was a I was a 400 intermediate hurdler. So I quarter mile race, you know, hurtling 10 obstacles on the race. And I had a terrible habit, had a terrible habit during my races of looking over my shoulder. you know you know i was in a good position when i was looking over my shoulder because i was looking behind me at someone uh but i had a bad habit of looking at the people i was running against right and my coach used to tell me to uh to run the race as though i had blinders on you know like in a like like i think horses you know they in horse races they wear these these blinders so so let's talk about that your perspective on uh you know running your business with with discipline and running your business with those blinders on so that you're not distracted by the noise. And there's a lot of it right now, the noise in the market. You know, I think it comes back to, you know, being focused on what you're trying to solve for. And I think it starts with spending your money as if you, you know, you only have a million or $1 million in the bank, you know, whatever it is, you need to have fundamental discipline in terms of what you're trying, the questions that you're trying to solve for and not take for granted that, you know, that the capital markets will always be there. Yeah. And I think the moment you get comfortable that the markets are going to be there, you've fallen into the trap. You know, I think you've suddenly you've you're you're opening yourself up. So and you're taking your blinders off. You know, I think you got to stay laser focused on the mission at hand and execute on your programs and not get not fall into the trap of what other people are doing. Because at the end of the day, it's it's your execution that's ultimately going to matter. And it's the data and the de-risking that you've done that matters. And if you're focusing on the right programs, the market opportunity is appropriate. And you're focusing on the right areas. So it comes back to your capital allocation. You know, it seems to me that if you if you focus on the fundamental execution of picking the right programs, answering the right questions and moving expeditiously. And that means getting, you know, doing things thoughtfully so that when you make a mistake, you're not making a mistake five times. You know, that you're putting in programs too quickly where if you get, if this works, doesn't work, that three other programs are going out. It's looking at, you know, where you are in terms of ordering phase three drug product materials when you're still in phase two. You know, you know, there's steps along the way that one should look at this in the same respect. You should be looking at ordering, you know, making sure that you've got clinical preclinical proofs of concept before you start going for large scale manufacturing. You know, I mean, there's a lot of times where people are saying you need your your your manufacturing slot. You need your material is now. So everybody's gaming everybody. and particularly in a market right now that's so hot, I'm certainly see where, I could see where people can make costly decisions before they need to. So I would just caution on gating, gate your expenses and, you know, think of them as blinders to going back to your analogy. But I would certainly stay true to yourself because at the end of the day, if you stay true to yourself, the hubris will come and go. But you're still going to have to be standing. Yeah, yeah. It's an interesting point. You alluded to getting ahead of yourself in terms of capacity. And I can see that being a very easy trap to fall into this manufacturing capacity. Looking at that prematurely, because there is, especially among CMOs in that entire industry, you know, there's a, there's a lot of hype around the fact that, hey, if you want in, you better get in now because it's, you know, so restricted right now. Although, you know, it seems like every, every day I open up my email, there's a story about a new, new CMO breaking, breaking ground, new CDMO breaking ground. So hopefully that capacity crunch is changing, but you know, all, all these, all these pressures, I think you have to acknowledge that it's difficult to keep those blinders on when so many people are advising that you pay attention to so many things and move proactively because of industry dynamics. Oh, absolutely. And when you're taking money from people, people are expecting execution. So, you know, the other thing I would caution, right, is making sure that the expectations that you're setting are realistic as well and that you can execute to those. Because I think the management of expectations are really important. And so there's a lot of different constituencies that you need to balance. And if people are saying certain things, you know, you want to be relevant, too. But again, to me, it comes down to your credibility and your integrity. And those things are going to matter. Right now, the market is buying everything. There's going to come down to a day where people are going to get rewarded for executing. Right now, people are not necessarily – the correlation of execution and access to capital is not in place. And that's another reason to be poised for some concern. You know, the underlying environment is very positive right now. You know, the Fed's got our back. A lot of liquidity out there, a lot of inflows right now. And that's manifesting itself that all deals are getting done. People are buying everything and valuations are not currently at a level that can be rationalized by most sell side analysts. So I think there's a legitimate question of durability that's in the market at this point in time. I'm involved with trying to tap into that now, too. And it's the elephant in the room. Sunny skies right now. There's no reason to be concerned. But when the markets are as hot as they are, it's just a warning, I think, that people should not consider this to be permanent. This won't last forever. And I guess the words of caution are just to be mindful of that and to run your business so it's unbridled from all the hubris and that you've got enough cash and you never have enough cash. So my suggestion is take it when you can and spend it thoughtfully. You want to move things expeditiously, but not recklessly for all the reasons that we've spoken about. Yeah. Yeah. Yeah, that's good risk mitigation advice. Is there risk, since I bring it up, is there risk mitigation advice beyond the capital context that you would share? You know, I would say indirectly. You know, the more money you have, you're going to do more things, arguably. And I would just say that everything has a dollar consequence generally in some way. But I would say given time, given opportunity cost, I think one of the great biggest things are there's opportunity cost with every decision that is made. And I'm not sure opportunity cost is considered. So when you're doing experiments that you kind of swing in for the fences, that if you weren't flush with cash, maybe you wouldn't consider such a thing. And maybe there's better program or better indication or something better to do with that money. So, you know, I would think of it in that context. Yeah, yeah. Well, good. It's been an enlightening conversation, Alan. I think to the point that you made about the place that we're in as an industry right now and the warning, if you will, hopefully things continue to move in a positive direction. but as we sort of paint our own paint you know our own picture of success as leaders of biopharma emerging biopharma companies these are crazy times and important things to keep in consideration as you move forward and I fully agree and you know and I think what's interesting is right now the capital markets are being very, I wouldn't say very disciplined. And so therefore, the allocation of capital is being spread evenly about. And I think that, you know, at some point, the pendulum is going to swing. And I'm not saying the party is going to be over. But I think it's natural that there's going to be some tightening and that the bars, they're going to raise the bar in terms of who they fund and who they don't fund. And I think, you know, the proxy is going to be how everyone executes with the money they have today and whether or not they deserve to be reloaded or not. So, you know, I think, you know, if you're focused in terms of how you're allocating and how you're executing, you know, I think at the end of the day, you'll be rewarded and people will reward you for it. But for those who blow the money that they have now, right, this is a unique opportunity to execute. And for those who don't take this seriously, who take this for granted, they may not have another chance. Yeah. Always good advice from Allan Shaw. I appreciate your coming back on the show. It's like I always say to my colleague, Erin Harris, when she joins me on these episodes, I appreciate your willingness to sacrifice your professional integrity by spending an hour with me on my podcast. That's a risk that I'm more than happy to continue to take. I appreciate it. Thanks again, Alan. It's always a pleasure. Same here. Same here. To be continued. Thanks a lot, man. Absolutely. So that's Allan Shaw. I'm Matt Pillar, and this is the Business of Biotech. We're produced by Bioprocess Online in partnership with Cytiva. You can find the former at bioprocessonline.com, where I kindly request that you subscribe to my newsletter. and at the latter you can find a trove of resources for new and emerging biotechs at citivalifesciences.com backslash emerging biotech before you go check those out subscribe to this podcast on whichever platform you prefer give us five stars if you like what you heard and as always thanks for listening